**NEPHROS INC** Form 3 October 01, 2007

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104 January 31,

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Expires: 2005

Estimated average burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

WEXFORD CAPITAL LLC

(Last)

(First) (Middle) Statement

(Month/Day/Year)

09/19/2007

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

NEPHROS INC [NEP]

4. Relationship of Reporting Person(s) to Issuer

Director

Officer

5. If Amendment, Date Original

Filed(Month/Day/Year)

411 WEST PUTNAM AVENUE

(Street)

(Check all applicable)

(give title below) (specify below)

\_X\_\_ 10% Owner Other

6. Individual or Joint/Group

Filing(Check Applicable Line) Form filed by One Reporting

Person

\_X\_ Form filed by More than One

Reporting Person

GREENWICH, CTÂ 06830

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities

Beneficially Owned (Instr. 4)

Ownership Form:

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership

(Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of

Derivative

5. Ownership Form of Derivative

Security:

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Expiration Date Exercisable

Date

Amount or Title Number of Shares

Security Direct (D) or Indirect (I)

(Instr. 5)

## Edgar Filing: NEPHROS INC - Form 3

Common Stock and Series A 10% Secured Warrants 21,246,459 By Lambda  $\hat{\mathbf{A}}^{(1)}$  $\hat{A}^{(2)}$ \$ 0.706 (4) Convertible Note due to Investors LLC (5) 2008 Purchase Common Stock

## **Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
WEXFORD CAPITAL LLC 411 WEST PUTNAM AVENUE GREENWICH, CT 06830	Â	ÂX	Â	Â
JACOBS JOSEPH X1Â	Â	ÂX	Â	Â
DAVIDSON CHARLES E X1Â	Â	ÂX	Â	Â

# **Signatures**

Arthur H. Amron as Partner and Secretary of Wexford Capital
LLC

\*\*Signature of Reporting Person

Date

Charles E. Davidson

\*\*Signature of Reporting Person

Date

Joseph M. Jacobs

10/01/2007

\*\*Signature of Reporting Person

Date

10/01/2007

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Note will automatically convert on the twenty-first (21st) day after the issuer sends or gives its stockholders a definitive Schedule (1) 14C information statement relating to certain actions taken by stockholders of the issuer by written consent (the ?Automatic Conversion Date?).
- (2) The maturity date of the Note is September 19, 2008.
  - The number reported includes 14,164,306 shares of Common Stock and warrants to purchase an additional 7,082,153 shares of Common Stock. The number of shares and warrants reported is based on the original principal amount of the Note (\$10,000,000). The Note accrues
- (3) interest at a rate of 10% per annum, and the accrued interest will automatically be converted into shares of Common Stock on the Automatic Conversion Date at the same conversion rate as the rate that applies to the original principal amount. The number of warrants issued upon conversion of the Note will increase by 50% of the number of shares of Common Stock issued with respect to the accrued interest.
- (4) The amount reported represents the conversion price used to determine the number of shares of Common Stock issuable upon the conversion of the Note. The exercise price of the warrants that will be issued upon the conversion of the Note is \$0.90 per share.

Reporting Owners 2

## Edgar Filing: NEPHROS INC - Form 3

- The Note is owned by Lambda Investors LLC (?Lambda?). Wexford Capital LLC (?Wexford?), as manager of Lambda, may be deemed to beneficially own the Note. Charles E. Davidson (?Davidson?) and Joseph M. Jacobs (?Jacobs?) are the managing members of
- (5) Wexford. Davidson and Jacobs may also be deemed to beneficially own the Note. Wexford, Davidson and Jacobs each disclaims beneficial ownership of the securities reported hereby and this report shall not be deemed as an admission that they are the beneficial owners of such securities except in the case of Davidson and Jacobs to the extent of their interests in each member of Lambda.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.